The bidding window for Studio LSD SME IPO was open from August 18, 2025, to August 20, 2025. The basis of allotment will be finalised today, August 21, 2025. Here’s how you can check the IPO allotment status on the NSE and registrar’s website.
Studio LSD IPO is a book-building issue of ₹74.25 crores, consisting of a fresh issue of ₹59.40 crores and an offer for sale (OFS) of ₹14.85 crores. The price band is set at ₹51 to ₹54 per share. The tentative listing date on NSE Emerge is August 25, 2025.
Corpwis Advisors Private Limited is the book-running lead manager, and Purva Shareregistry (India) Private Limited is the registrar for the IPO.
Check out newly Listed IPOs on BSE and NSE.
The net proceeds from the fresh issue will be used to fund:
(August 20, 2025, end of the day)
Category |
Subscription (times) |
Qualified Institutional Investors (QIBs) |
1.00 |
Non-Institutional Investors (NIIs) |
1.25 |
Individual Investors (IND category bidding for 2 Lots) |
4.58 |
Total |
3.23 |
As of 21 August 2025, Studio LSD IPO GMP stood at nil. The shares are expected to list at par with the issue price of ₹54..
Source: Business Standard Report dated 21 August, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Studio LSD is a multimedia production house that partners with artists from the film and television industry to create original and captivating stories. This includes every aspect from idea to distribution and financing the projects, hiring actors and crew members, finding locations, creating sets, managing the budgets, and overseeing the entire production and post-production process.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.